---
id: 071
title: Acyclovir/Valacyclovir Mechanism and Spectrum
category: antimicrobials
subcategory: antivirals_herpes
tags: [acyclovir, valacyclovir, HSV, VZV, mechanism, prodrug]
difficulty: medium
---

## Question

What is acyclovir's mechanism and why is valacyclovir preferred for oral therapy? Use the **"VIRAL TK Activates"** mnemonic.

## Answer

### **"VIRAL TK Activates" Mnemonic:**

**VIRAL:**
- **V**iral thymidine kinase (TK) required
- **I**nhibits viral DNA polymerase
- **R**equires phosphorylation (3 steps)
- **A**cyclic guanosine analog
- **L**acks 3'-OH group → chain termination

**TK Activates:**
- **T**hymidine **K**inase (viral enzyme) = key
- **A**cti vates prodrug (acyclovir)
- **C**oncentrated in infected cells only
- **T**riphosphate form = active
- **I**ncorporated into viral DNA
- **V**alacyclovir = better bioavailability
- **A**cyclovir bioavailability only 10-20%
- **T**ermination of DNA chain
- **E**xcellent safety (selective)
- **S**elective toxicity (viral TK required)

### **Mechanism of Action:**

**Step 1: Selective Activation**
- **Viral thymidine kinase** (TK) phosphorylates acyclovir → acyclovir monophosphate
- Human cells lack this enzyme → **selective activation** in infected cells only

**Step 2: Further Phosphorylation**
- Cellular kinases convert to acyclovir triphosphate (active form)
- Concentrations **100× higher** in infected vs uninfected cells

**Step 3: Inhibition of Viral DNA Polymerase**
- Acyclovir triphosphate competes with deoxyguanosine triphosphate (dGTP)
- Incorporated into viral DNA
- **Lacks 3'-OH group** → **obligate chain termination**
- Viral DNA synthesis stops

**Selectivity:** Only viruses with TK enzyme activate acyclovir → safe for humans

### **Spectrum of Activity:**

| Virus | Activity (IC50) | Clinical Use |
|-------|-----------------|--------------|
| **HSV-1** | Excellent (0.04 µg/mL) | Orolabial herpes, encephalitis |
| **HSV-2** | Excellent (0.10 µg/mL) | Genital herpes |
| **VZV** | Good (0.50 µg/mL) | Shingles, varicella |
| **EBV** | Moderate | Limited clinical use |
| **CMV** | Poor | NOT effective (use ganciclovir) |

**Key:** VZV requires **higher doses** than HSV (10 mg/kg vs 5 mg/kg IV)

## Key Points

### **Valacyclovir vs Acyclovir:**

| Feature | Acyclovir | Valacyclovir |
|---------|-----------|--------------|
| **Bioavailability (PO)** | **10-20%** (poor) | **54%** (excellent) |
| **Dosing frequency** | 5× daily (q4-5h while awake) | **2-3× daily** |
| **IV formulation** | YES | NO (oral only) |
| **Active drug** | Acyclovir | **Prodrug** → converted to acyclovir |
| **Cost** | Cheaper | More expensive |
| **Compliance** | Poor (frequent dosing) | **Better** (less frequent) |

**Clinical Pearl:** Valacyclovir is L-valyl ester **prodrug** of acyclovir with **3-5× better bioavailability**

### **Key Dosing Examples:**

**HSV Encephalitis:**
- Acyclovir **10 mg/kg IV q8h** × 14-21 days (higher dose than other HSV)

**Genital HSV (first episode):**
- Valacyclovir **1g PO BID** × 7-10 days
- Acyclovir 400mg PO 5× daily × 7-10 days (less convenient)

**Herpes Zoster (Shingles):**
- Valacyclovir **1g PO TID** × 7 days
- Acyclovir 800mg PO 5× daily × 7 days

**HSV Suppression:**
- Valacyclovir **500mg-1g PO daily**
- Acyclovir 400mg PO BID

### **Clinical Pearls:**
- **Valacyclovir preferred** for oral therapy (better bioavailability, less frequent dosing)
- **Acyclovir IV** for severe infections (encephalitis, disseminated)
- **VZV requires higher doses** than HSV (less sensitive)
- **Selective activation** by viral TK → excellent safety profile
- **CMV NOT covered** (CMV lacks viral TK → use ganciclovir)
- Start within **72 hours** of symptom onset for shingles (maximal benefit)

## Sources

- [StatPearls NBK542180: Acyclovir 2024]
- [NCBI Books: Antiviral Therapy of HSV-1 and HSV-2]
- [AAC 2020: Acyclovir/Valacyclovir Population PK]

## Media

N/A
